MHE November 2020

Prime Therapeutics research a thumbs up for Entresto — with caveats

November 18, 2020

Entresto (sacubitril-valsartan) didn’t get a lot of love from payers after it was approved in 2015 because of its expense and the crowded armamentarium for heart failure. But Entresto has since made its way into guidelines for reduced ejection fraction heart failure, sometimes called systolic heart failure.

Bringing CAR-T Cell Therapy to the Community

November 23, 2020

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

U.S. Looks Bad in International COVID-19 Comparisons

November 18, 2020

The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.

5 More Takeaways About the Telehealth Boom

November 26, 2020

The second of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

5 Takeaways About the Telehealth Boom

November 25, 2020

The first of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

Partners in Primary Care Finds Success in Addressing Seniors’ Social Determinants of Health

November 19, 2020

There is growing recognition among healthcare providers and payers that disease prevalence is inextricably tied to social and environmental factors that impact health. In fact, clinical care accounts for an estimated 20% of health outcomes, while 80% are the result of social determinants of health (SDOH).